Related Experiment Video
Updated: Mar 3, 2026

Culture and Imaging of Ex Vivo Organotypic Pseudomyxoma Peritonei Tumor Slices from Resected Human Tumor Specimens
Published on: December 9, 2022
Multiple components of PKA and TGF-β pathways are mutated in pseudomyxoma peritonei
Lilli Saarinen1, Pirjo Nummela1, Alexandra Thiel1
1Genome-Scale Biology Research Program, Research Programs Unit, University of Helsinki, Helsinki, Finland.
Abstract:
Pseudomyxoma peritonei (PMP) is a subtype of mucinous adenocarcinoma mainly restricted to the peritoneal cavity and most commonly originating from the appendix. The genetic background of PMP is poorly understood and no targeted treatments are currently available for this fatal disease. While RAS signaling pathway is affected in most if not all PMP cases and over half of them also have a mutation in the GNAS gene, other genetic alterations and affected pathways are, to a large degree, poorly known. In this study, we sequenced whole coding genome of nine PMP tumors and paired normal tissues in order to identify additional, commonly mutated genes and signaling pathways affected in PMP. These exome sequencing results were validated with an ultra-deep amplicon sequencing method, leading to 14 validated variants. The validated results contain seven genes that contribute to the protein kinase A (PKA) pathway. PKA pathway, which also contains GNAS, is a major player of overproduction of mucin, which is the characteristic feature of PMP. In addition to PKA pathway, we identified mutations in six genes that belong to the transforming growth factor beta (TGF-β) pathway, which is a key regulator of cell proliferation. Since either GNAS mutation or an alternative mutation in the PKA pathway was identified in 8/9 patients, inhibition of the PKA pathway might reduce mucin production in most of the PMP patients and potentially suppress disease progression.
Insights
Pseudomyxoma peritonei (PMP) research identified new genetic targets. Mutations in the protein kinase A (PKA) pathway, crucial for mucin overproduction, were found in most PMP tumors, offering potential therapeutic strategies.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Pseudomyxoma peritonei (PMP) is a rare mucinous adenocarcinoma with unknown genetic drivers.
- Current treatments for PMP are limited, highlighting the need for targeted therapies.
Purpose of the Study:
- To identify novel genetic alterations and affected signaling pathways in PMP.
- To explore potential therapeutic targets for PMP based on genetic findings.
Main Methods:
- Whole-exome sequencing of nine PMP tumors and paired normal tissues.
- Validation of identified variants using ultra-deep amplicon sequencing.
Main Results:
- Identified 14 validated genetic variants, including seven genes in the protein kinase A (PKA) pathway.
- Mutations in the PKA pathway (including GNAS) were present in 8/9 patients, suggesting a key role in mucin overproduction.
- Discovered mutations in six genes within the transforming growth factor beta (TGF-β) pathway, a regulator of cell proliferation.
Conclusions:
- The PKA pathway is frequently altered in PMP and may be a therapeutic target to reduce mucin production.
- Targeting the PKA pathway could potentially suppress PMP progression.
More Related Videos
06:54Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
Related Concept Videos
TGF - β Signaling Pathway
Abnormal Proliferation
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The Tumor Microenvironment
PI3K/mTOR/AKT Signaling Pathway